Mitotane Not Needed With Low- to Intermediate-Risk Adrenocortical Carcinoma

TUESDAY, Sept. 5, 2023 -- Mitotane does not show a significant improvement in the relapse rate and is associated with adverse events in patients with adrenocortical carcinoma considered to be at low-to-intermediate risk for recurrence, according to...